Comparative analysis of treatment with either dipyridamol or combination dipyridamol plus aspirin in patients selected for secondary stroke prevention

57 patients were treated with dipyridamol (225 mg/day) alone and in combina tion with aspirin (150 mg/ and 50 mg/day respectively) since the 15th day o f stroke onset. 16 patients were enrolled as controls. Development of vascu lar events and results of spontaneous and ADP induced aggregation rates wer e assessed. We found that such therapy applied for six months could prevent the development of myocardial infarction, ischemic stroke and other vascul ar events whereas in 19% of patients who weren't treated recurrent ischemic stroke occurred. It is shown that both monotherapy with dipyridamol and co mbination therapy with dipyridamol+aspirin has stabilized aggregation withi n normal parameters by the middle of the treatment course irrespectively of platelet functional activity registered before treatment start.